Hoffmann-La Roche Inc. Patent applications |
Patent application number | Title | Published |
20160138004 | Amino Acid Sequence Presenting Fusion Polypeptide And Its Use - Herein is reported a fusion polypeptide according to formula I | 05-19-2016 |
20160137643 | 1,7-NAPHTHYRIDINE DERIVATIVES - The present invention relates to compounds of general formula I wherein R | 05-19-2016 |
20160130255 | ETHYNYL DERIVATIVES - The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD). | 05-12-2016 |
20160122363 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION - The invention provides novel compounds having the general formula: | 05-05-2016 |
20160122344 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection - The invention provides novel compounds having the general formula: | 05-05-2016 |
20160102149 | OPTIMIZING THE PRODUCTION OF ANTIBODIES - A general method is provided for the production of purified antibodies by separation of an antibody molecule from an antibody variant by chromatographic methods, e.g. to enhance therapeutic efficacy, by for example choosing a specific harvesting time point and/or a specific purification scheme. The current invention thus reports a method for producing an antibody composition comprising an antibody molecule and a variant thereof, comprising the following steps: providing a sample comprising the antibody molecule and a variant thereof, determining the presence of the antibody molecule and/or a variant thereof and/or the ratio of the amount of the antibody molecule or variant thereof to the sum of the amounts of the antibody molecule and the variant thereof, in an aliquot of said sample, determining a subsequent harvesting time point and/or antibody purification scheme on basis of the data obtained before, thereby producing an antibody composition comprising the antibody molecule and a variant thereof. | 04-14-2016 |
20160095844 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES - The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula | 04-07-2016 |
20160083383 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection - The invention provides novel compounds having the general formula: | 03-24-2016 |
20160083357 | NOVEL TETRAZOLONE DERIVATIVES - The invention relates to a compound of formula (I) | 03-24-2016 |
20160077100 | Specific Detection of Rat Antibodies in Mouse Serum - One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of
| 03-17-2016 |
20160075785 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-17-2016 |
20160075688 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS - The invention provides novel compounds having the general formula (I) | 03-17-2016 |
20160075687 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS - The invention provides novel compounds having the general formula (I) | 03-17-2016 |
20160075686 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS - The invention provides novel compounds having the general formula (I) | 03-17-2016 |
20160074360 | COMBINED DRUG ADMINISTRATION OF DALCETRAPIB AND ORLISTAT - The present invention is directed to the combined administration of a thioester therapeutic agent (preferably of formula I) and at least one esterase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for increasing the bioavailability of said thioester for the treatment and prophylaxis of a cardiovascular disorder. | 03-17-2016 |
20160068602 | SEQUENCE DEPENDENT AGGREGATION - Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution. | 03-10-2016 |
20160068531 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION - The invention provides novel compounds having the general formula: | 03-10-2016 |
20160060270 | New Aryl-Quinoline Derivatives - The invention provides novel compounds having the general formula (I) | 03-03-2016 |
20160053015 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 02-25-2016 |
20160052921 | NOVEL 4-METHYL-DIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION - The invention provides novel compounds having the general formula: | 02-25-2016 |
20160046637 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR AGONISTS - The invention relates to a compound of formula (I) | 02-18-2016 |
20160046631 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS - The invention relates to a compound of formula (I) | 02-18-2016 |
20160046628 | Pd-CATALYZED COUPLING OF PYRAZOLE AMIDES - A novel process for the preparation of imidazo[1,2-a]pyridine compounds of the formula | 02-18-2016 |
20160046583 | ISOQUINOLINE DERIVATIVES - The present invention relates to the use of compounds of general formula | 02-18-2016 |
20160045597 | COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1 - The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3 | 02-18-2016 |
20160039787 | Arylethynyl derivatives - The present invention relates to ethynyl derivatives of formula I | 02-11-2016 |
20160031878 | RADIOLABELED COMPOUNDS - The present invention relates to radiolabeled compounds of formula I | 02-04-2016 |
20160016968 | NOVEL PYRIDINE DERIVATIVES - The invention relates to a compound of formula (I) | 01-21-2016 |
20160016963 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one - The present invention relates to compounds of general formula I | 01-21-2016 |
20160002346 | HER1 ANTIGEN BINDING PROTEINS BINDING TO THE BETA-HAIRPIN OF HER1 - The invention relates to anti-HER1 antigen binding proteins, e.g. anti-HER1 antibodies, that bind to the beta-hairpin of HER1, methods for selecting these antigen binding proteins, their preparation and use as medicament. | 01-07-2016 |
20160002338 | ANTI-HER3 ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3 - The invention relates to specific anti-HER3 antibodies, that bind to the beta-hairpin of HER3, their preparation and use as medicament. | 01-07-2016 |
20160002207 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES - The invention provides novel compounds having the general formula (I) | 01-07-2016 |
20160002177 | COMT INHIBITORS - The present invention relates to compounds of formula | 01-07-2016 |
20160002152 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS - The invention provides novel compounds having the general formula (I) | 01-07-2016 |
20160000760 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. | 01-07-2016 |
20150376674 | Use of an amino acid auxotrophy cured prokaryotic strain for the recombinant production of a polypeptide - Herein is reported a method for producing a polypeptide in a prokaryotic cell, comprising the step of cultivating a prokaryotic cell comprising one or more nucleic acids encoding the polypeptide in a chemically defined minimal growth medium and recovering the polypeptide from the prokaryotic cell or the periplasm of the prokaryotic cell or from the medium, wherein the prokaryotic cell is an amino acid auxotrophy cured prokaryotic cell, wherein growth of the amino acid auxotrophy cured prokaryotic cell compared to the non-cured prokaryotic cell under the same cultivation conditions and in the same growth medium requires the supplementation of fewer amino acids to the growth medium, and wherein the chemically defined minimal growth medium is free of the amino acid corresponding to the auxotrophy that has been cured in the auxotrophy cured prokaryotic cell. | 12-31-2015 |
20150376194 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS - The invention provides novel compounds having the general formula (I) | 12-31-2015 |
20150376192 | NOVEL PYRAZOL DERIVATIVES - The invention relates to a compound of formula (I) | 12-31-2015 |
20150376180 | DIHYDROQUINOLINE-2-ONE DERIVATIVES - The invention provides novel compounds having the general formula (I) | 12-31-2015 |
20150376166 | INHIBITORS OF BRUTON'S TYROSINE KINASE - This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. | 12-31-2015 |
20150376165 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. | 12-31-2015 |
20150368256 | NEW BICYCLICPYRIDINE DERIVATIVES - The invention provides novel compounds having the general formula (I) | 12-24-2015 |
20150361034 | NEW PROCESS - A process for the preparation of a compound of formula (I): | 12-17-2015 |
20150353893 | METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIOMYOCYTES - This application relates to a method for differentiating pluripotent stem cells (PSCs) into cardiomyocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) into defined cardiomyocytes based on linked steps of chemically defined medium inductions. | 12-10-2015 |
20150353640 | ANTIBODY FORMULATION - The present invention relates to a pharmaceutical formulation comprising an anti-CD20 antibody. The formulation may additionally comprise a buffer, a surfactant and/or an isotonicity agent. | 12-10-2015 |
20150353559 | NEW BICYCLIC DERIVATIVES - The invention provides novel compounds having the general formula (I) | 12-10-2015 |
20150353511 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I: | 12-10-2015 |
20150352204 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of E-selectin, ICAM-1 or VEGFR-3 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. | 12-10-2015 |
20150344586 | Disulfide-Linked Multivalent MHC Class I Comprising Multi-function Proteins - Herein is reported a disulfide-linked multivalent multi-function protein, characterized in that it comprises two or more antigen presenting domains, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a β2-microglobulin, and (ii) the extracellular domains α1, α2, and α3 of a class I MHC molecule with a relative frequency of less than 1%, or (i) a T-cell response eliciting peptide, (ii) a β2-microglobulin, and (iii) the extracellular domains α1, α2, and α3 of a class I MHC molecule with a relative frequency of 1% or more, wherein the antigen binding site binds to a cancer cell surface antigen or a virus-infected cell surface antigen and wherein the antigen presenting domain has at least two non-naturally occurring cysteine residues which form an intrachain/interdomain disulfide bond. | 12-03-2015 |
20150336951 | Process For The Preparation Of A DPP-IV Inhibitor - The present invention is concerned with an improved process for the preparation of pyrido[2,1-a]isoquinoline derivatives of formula I | 11-26-2015 |
20150322149 | BLOOD BRAIN BARRIER SHUTTLE - The present invention relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same. | 11-12-2015 |
20150322058 | Oxytocin receptor agonists for the treatment of CNS diseases - The invention relates to the use of a compound of formula I | 11-12-2015 |
20150322054 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors - The present invention provides 4-(3-Amino-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamines of formula I | 11-12-2015 |
20150315296 | MULTISPECIFIC ANTIBODIES - The present invention relates to multispecific antibodies, their manufacture and use. | 11-05-2015 |
20150315165 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE - A novel process for the preparation of a fluorolactone derivative of the formula | 11-05-2015 |
20150307472 | NOVEL PYRIDINE DERIVATIVES - The invention relates to a compound of formula (I) | 10-29-2015 |
20150307461 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I: | 10-29-2015 |
20150307452 | NOVEL PYRIDINE DERIVATIVES - The invention relates to a compound of formula (I) wherein R | 10-29-2015 |
20150306130 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY - The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X | 10-29-2015 |
20150299688 | CO2 PROFILE CULTIVATION - A dissolved CO | 10-22-2015 |
20150299220 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS - The invention relates to a compound of formula (I) wherein R | 10-22-2015 |
20150299194 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS - This invention relates to novel 4-amino-imidazoquinoline compounds of the formula | 10-22-2015 |
20150299165 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS - The invention relates to CB2 agonists of formula (I) wherein R | 10-22-2015 |
20150291704 | METHOD FOR THE PRODUCTION AND SELECTION OF MOLECULES COMPRISING AT LEAST TWO DIFFERENT ENTITIES AND USES THEREOF - Herein is reported a method for producing a polypeptide comprising at least two polypeptide domains comprising the step of cultivating a cell comprising (a) a nucleic acid encoding a soluble | 10-15-2015 |
20150291530 | PROCESS FOR THE PREPARATION OF 2-TRIFLUOROMETHYL ISONICOTINIC ACID AND ESTERS - The invention relates to a novel process for the preparation of 2-trifluoromethyl isonicotinic acid and esters of the formula I which involves a palladium catalysed carbonylation or cyanation step wherein R | 10-15-2015 |
20150284457 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 10-08-2015 |
20150284434 | PEPTIDES AS OXYTOCIN AGONISTS - The invention relates to compounds of formula | 10-08-2015 |
20150284386 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS - The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula | 10-08-2015 |
20150283238 | Tumor Therapy with an Antibody for Vascular Endothelial Growth Factor and an Antibody for Human Epithelial Growth Factor Receptor Type 2 - The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions. | 10-08-2015 |
20150275260 | METHOD FOR THE PRODUCTION OF POLYPEPTIDES IN THE PERIPLASM OF PROKARYOTIC CELLS - Herein is reported a method for producing a polypeptide comprising the step of incubating (resuspended) prokaryotic cells in a solution comprising about 10 mM to about 95 mM Tris-HCl and about 2 mM to about 6 mM EDTA at a pH value of about 7 to about 10 for about 15 min to about 6 h at about 25° C. | 10-01-2015 |
20150274831 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 10-01-2015 |
20150274830 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 10-01-2015 |
20150274773 | PURIFICATION OF POLYPEPTIDES USING DUAL STAGE TANGENTIAL-FLOW ULTRAFILTRATION - The present invention is directed to methods for the separation of a molecule of interest from a solution containing the molecule using dual stage tangential-flow ultrafiltration (“TFF”). In particular, the methods of the invention are directed to the processing of crude feed streams such as conditioned cell culture supernatant to dramatically reduce contaminant and/or impurity levels prior to subsequent, i.e., downstream, refining unit operations. The methods of the invention may be used in the processing of a crude feed stream from biological production systems such as fermentation or other cell culture process, and may further eliminate the need for time consuming impurity precipitation (e.g., pH driven) and/or precipitate filtration processes prior to downstream processes that are sensitive to high impurity loads such as chromatographic unit operations. The disclosed dual stage TFF process combines at least two TFF unit operations that may be advantageously conducted at a pH that corresponds to or is about that of the pH of the feed stream, e.g., a cell culture supernatant, typically a pH of 7.5±1.0. The use of the TFF unit operations to supplement, improve or replace traditional processes for purification of proteins of interest for a feed stream may represent significant savings in both direct and indirect processing costs, For example, in addition to indirect savings by eliminating precipitation and precipitate filtration processes, the reduction in impurity loads effected by the dual stage TFF unit operations may result in indirect savings by improving downstream column performance, e.g., chromatographic separation, dynamic binding capacity, operational lifetime and/or a reduction of the required column size. In particular embodiments, the methods of the invention are used in processes for the purification of immunoglobulin molecules, e.g., antibodies, which processes are devoid of affinity purification steps, e.g., protein A affinity chromatography purification. | 10-01-2015 |
20150274711 | Antiviral Compounds - The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 10-01-2015 |
20150274661 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS - The present invention provides compounds of formula (I), wherein Z, R | 10-01-2015 |
20150273023 | Use of PEGylated IGF-I Variants For The Treatment Of Neuromuscular Disorders - The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where the PEG is attached to at least one lysine residue. The invention also relates to methods for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS) by administering a therapeutically effective amount of the pharmaceutical composition of the invention. | 10-01-2015 |
20150266878 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER - The invention provides novel compounds having the general formula: | 09-24-2015 |
20150259341 | IMIDAZOPYRIDINE DERIVATIVES - The present invention relates to compounds of general formula | 09-17-2015 |
20150259334 | BENZISOXAZOLES - The present invention relates to compounds of general formula | 09-17-2015 |
20150258209 | COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES - Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof. | 09-17-2015 |
20150252057 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection - The invention provides novel compounds having the general formula: | 09-10-2015 |
20150252049 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS - This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of Autistic Spectrum Disorder (ASD), in particular, autism. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of ASD comprising a compound according to the invention and a pharmaceutically acceptable carrier. | 09-10-2015 |
20150252044 | SUBSTITUTED 1,6-NAPHTHYRIDINES - The present invention relates to the use of compounds of general formula | 09-10-2015 |
20150252039 | Process For The Preparation Of Pyrido[2,1-a] Isoquinoline Derivatives By Catalytic Asymmetric Hydrogenation Of An Enamine - The invention relates to a process for the preparation of pyrido[2,1-a]isoquinoline derivatives of the formula | 09-10-2015 |
20150250725 | METHOD FOR PRODUCING A LIPID PARTICLE, THE LIPID PARTICLE ITSELF AND ITS USE - A method for producing a lipid particle comprising the following: i) providing a first solution comprising denatured apolipoprotein, ii) adding the first solution to a second solution comprising at least two lipids and a detergent but no apolipoprotein, and iii) removing the detergent from the solution obtained in ii) and thereby producing a lipid particle. | 09-10-2015 |
20150246961 | METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS - Herein is reported a method for recombinantly producing a polypeptide in a cell comprising the step of cultivating a cell which comprises a nucleic acid encoding the polypeptide, and recovering the polypeptide from the cell or the cultivation medium, wherein each of the amino acid residues of the polypeptide is encoded by at least one codon, whereby the different codons encoding the same amino acid residue are combined in one group and each of the codons in a group is defined by a specific usage frequency within the group, whereby the sum of the specific usage frequencies of all codons in one group is 100%, and wherein the usage frequency of a codon in the polypeptide encoding nucleic acid is about the same as its specific usage frequency within its group. | 09-03-2015 |
20150246922 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE - The present invention relates to compounds of general formula I | 09-03-2015 |
20150246918 | IMIDAZOPYRIDINE DERIVATIVES - The invention is concerned with a compound of formula (I) | 09-03-2015 |
20150246906 | NOVEL ACETAMIDE DERIVATIVES - The invention is concerned with a compound of formula (I) | 09-03-2015 |
20150246894 | NOVEL OXAZOLIDINONE COMPOUNDS - The invention provides compounds having the general formula I | 09-03-2015 |
20150239969 | TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY - The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody. | 08-27-2015 |
20150239947 | CELL-PENETRATING PEPTIDES AND USES THEREOF - The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles. | 08-27-2015 |
20150239873 | SUBSTITUTED CARBAMATE COMPOUNDS - The invention is concerned with the compounds of formula (I): | 08-27-2015 |
20150238628 | ANTI-THEOPHYLLINE ANTIBODIES AND METHODS OF USE - The invention provides anti-theophylline antibodies and methods of using the same. | 08-27-2015 |
20150232577 | ANTI-BIOTIN ANTIBODIES AND METHODS OF USE - The invention provides anti-biotin antibodies and methods of using the same. | 08-20-2015 |
20150232561 | METHOD FOR SELECTION AND PRODUCTION OF TAILOR-MADE HIGHLY SELECTIVE AND MULTI-SPECIFIC TARGETING ENTITIES CONTAINING AT LEAST TWO DIFFERENT BINDING ENTITIES AND USES THEREOF - Herein is reported a method for producing a bispecific antibody comprising the step of incubating
| 08-20-2015 |
20150232560 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF - Herein is reported a method for determining a combination of antigen binding sites comprising the steps of (i) determining the binding specificity and/or affinity and/or effector function and/or in vivo half-life of a multitude of bispecific antibodies prepared by combining each member of a first multitude of antibody Fab fragments or scFv antibody fragments with each member of a second multitude of antibody Fab fragments or scFv antibody fragments, and a linker comprising at one of its termini the second member of the first binding pair and at the respective other terminus the second member of the second binding pair, whereby the first multitude specifically binds to a first cell surface molecule and the second multitude specifically binds to a second cell surface molecule, and (ii) choosing the bispecific antibody with suitable binding specificity and/or affinity and/or effector function and/or in vivo half-life and thereby determining a combination of antigen binding sites. | 08-20-2015 |
20150232548 | Combination therapy with an anti-ANG2 antibody and a CD40 agonist - The present invention relates to the combination therapy of an antibodies that binds to human angiopoietin 2 (ANG-2) with a CD40 agonist. | 08-20-2015 |
20150232541 | METHOD FOR MAKING ANTIBODY FC-REGION CONJUGATES COMPRISING AT LEAST ONE BINDING ENTITY THAT SPECIFICALLY BINDS TO A TARGET AND USES THEREOF - Herein is reported a method for producing an antibody Fc-region conjugate comprising as first component an antibody Fc-region and as second component at least one binding entity that specifically binds to a target using a transpeptidase for enzymatic conjugation of the antibody Fc-region to at least one binding entity. | 08-20-2015 |
20150232472 | TRIAZOLO COMPOUNDS - The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders. | 08-20-2015 |
20150225385 | Ethynyl Derivatives - The present invention relates to ethynyl derivatives of formula I | 08-13-2015 |
20150225345 | Ethynyl Derivatives - The present invention relates to ethynyl derivatives of formula I | 08-13-2015 |
20150225344 | Ethynyl Derivatives - The present invention relates to ethynyl derivatives of formula I | 08-13-2015 |
20150218250 | METHOD FOR PRODUCING MONOMERIC AND MULTIMERIC MOLECULES AND USES THEREOF - Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (B | 08-06-2015 |
20150218144 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS - The invention is concerned with the compounds of formula (I): | 08-06-2015 |
20150218141 | SUBSTITUTED CARBAMATE COMPOUNDS - The invention is concerned with the compounds of formula (I): | 08-06-2015 |
20150218133 | 6-AMINOINDOLE DERIVATIVES AS TRP CHANNEL ANTAGONISTS - The invention is concerned with the compounds of formula (I) | 08-06-2015 |
20150218131 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF - The present invention relates to compounds of formula | 08-06-2015 |
20150210704 | INHIBITORS OF BRUTON'S TYROSINE KINASE - This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. | 07-30-2015 |
20150210682 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection - The invention provides novel compounds having the general formula: | 07-30-2015 |
20150203472 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS - The present invention relates to compounds of general formula | 07-23-2015 |
20150198608 | METHOD FOR THE DETECTION OF A MULTISPECIFIC BINDER - Herein is reported a method for the detection of a multispecific antibody in a sample, whereby the multispecific antibody is specifically bound by i) a first anti-idiotypic antibody binding to a first binding specificity of the multispecific antibody, and ii) by a second anti-idiotypic antibody binding to a second binding specificity of the multispecific antibody and the formed complex is determined. | 07-16-2015 |
20150197510 | Arylethynyl derivatives - The present invention relates to ethynyl derivatives of formula I | 07-16-2015 |
20150197509 | SUBSTITUTED SULFONAMIDE SOLUTIONS - The invention is concerned with the compounds of formula (I): | 07-16-2015 |
20150191535 | BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG2 ANTIBODIES - The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 07-09-2015 |
20150191458 | TRIAZOLE CARBOXAMIDES AND USES THEREOF - The invention relates to compounds of formula | 07-09-2015 |
20150183778 | New non-annulated thiophenylamides - The invention provides novel compounds having the general formula (I) | 07-02-2015 |
20150182505 | SOLID FORMS OF (S)-2-METHOXY-3--PROPIONIC ACID AND OF SALTS THEREOF - The present invention relates to solid forms of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid, and of salts of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid. | 07-02-2015 |
20150175952 | STIRRER SYSTEM - The present invention concerns a stirrer system for animal cell culture consisting of a combination of at least one radially-conveying stirrer element and at least one axially-conveying stirrer element, wherein at least three stirrer elements must be present and the uppermost stirrer element is an axially-conveying stirrer element. The stirrer elements are arranged at a certain distance above one another on a stirrer shaft. A particular embodiment is a multiple stirrer system consisting of two disk stirrers as radially-conveying stirrer elements and an inclined-blade stirrer as an axially-conveying stirrer element wherein the inclined-blade stirrer is arranged above the disk stirrer on the stirrer shaft. The stirrer system according to the invention achieves among others a gentler and better intermixing in the culture of shear-sensitive mammalian cells in cell cultures. | 06-25-2015 |
20150175696 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 06-25-2015 |
20150175594 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS - The invention provides novel compounds having the general formula (I) | 06-25-2015 |
20150158950 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 06-11-2015 |
20150158879 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection - The invention provides novel compounds having the general formula: | 06-11-2015 |
20150158848 | Arylethynyl pyrimidines - The present invention relates to ethynyl derivatives of formula I | 06-11-2015 |
20150158818 | PROCESS FOR THE PREPARATION OF PYRAZOLE CARBOXYLIC ACID DERIVATIVES - The present invention relates to a novel process for the preparation of a pyrazole carboxylic acid derivative of the formula | 06-11-2015 |
20150158815 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER - The invention provides novel compounds having the general formula: | 06-11-2015 |
20150157739 | Imidazo[2,1]thiazol-3-one derivatives - The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula | 06-11-2015 |
20150152058 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS - This invention relates to novel 3-aminopyridines of the formula | 06-04-2015 |
20150148363 | NEW AZACYCLIC COMPOUNDS - The invention provides novel compounds having the general formula (I) | 05-28-2015 |
20150148332 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS - The present invention provides compounds of formula (Ia) and (Ib) | 05-28-2015 |
20150140683 | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF - Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof. | 05-21-2015 |
20150133505 | Arylethynyl derivatives - The present invention relates to ethynyl derivatives of formula I | 05-14-2015 |
20150133440 | DIFLUORO-HEXAHYDRO-CYCLOPENTAOXAZINYLS AND DIFLUORO-HEXAHYDRO-BENZOOXAZINYLS AS BACE1 INHIBITORS - The present invention provides difluoro-cyclopentaoxazinyls and difluoroenzooxazinyls of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. | 05-14-2015 |
20150132802 | ALKALINE FEED - A method for cultivating a bacterial cell comprising the addition of an amino acid in an alkaline solution used for pH regulation. Also an aspect is a method for producing a polypeptide comprising the steps of a) providing a bacterial cell comprising a nucleic acid encoding the polypeptide, b) cultivating the provided cell, c) adjusting the pH value during the cultivating with a basic solution comprising an amino acid, d) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide | 05-14-2015 |
20150132781 | MULTIPLEXED CHROMATOGRAPHY-IMMUNOASSAY METHOD FOR THE CHARACTERIZATION OF CIRCULATING IMMUNE COMPLEXES - Thus, herein is reported a method for analyzing/characterizing circulating immune complexes (CICs) formed in vivo comprising a size-exclusion chromatography of a sample obtained from a mammal to which the drug had been administered at least once for determining the weight/size of the immune complexes, optionally a second non-SEC chromatography, and at least one immunoassay, whereby the immune complex is characterized by the correlation of the immune complex size and the immunoassay result/read-out. Also reported herein is the use of a method as reported herein for determining a correlation to altered pharmacokinetics, for determining loss or reduction of efficacy, for determining neutralization of natural counterparts of the drug, for determining immune and hypersensitivity reactions, including serum sickness/type III hypersensitivity reaction/immune complex-mediated disease. | 05-14-2015 |
20150132307 | BISPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN 1L17 AND USES THEREOF - The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof | 05-14-2015 |
20150126743 | Process For The Preparation Of Pyrido [2,1-A] Isoquinoline Derivatives Comprising Optical Resolution Of An Enamine - This invention relates to a process for the preparation of pyrido[2,1-a]isoquinoline derivatives of the formula | 05-07-2015 |
20150111886 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS - The invention relates to a compound of formula (I) | 04-23-2015 |
20150111211 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 04-23-2015 |
20150099735 | TRIAZOLOPYRIDINE COMPOUNDS - The invention is concerned with triazolopyridine compounds of formula (I) | 04-09-2015 |
20150099734 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE - The invention provides novel compounds having the general formula (I) | 04-09-2015 |
20150098988 | COMBINATION THERAPY FOR THE TREATMENT OF OVARIAN CANCER - This invention concerns methods of treating a patient diagnosed with a platinum-resistant ovarian cancer comprising administering to said patient an effective amount of an anti-VEGF antibody and a chemotherapeutic. | 04-09-2015 |
20150087644 | PYRROLIDINO HETEROCYCLES - The invention relates to compounds of formula I | 03-26-2015 |
20150080556 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-19-2015 |
20150073173 | LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES - The invention relates to compounds of the formula | 03-12-2015 |
20150073129 | Combination therapy of antibodies against human CSF-1R and antibodies agains human PD-L1 - The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1. | 03-12-2015 |
20150072359 | METHOD FOR THE DETECTION OF FREE BINDING PARTNER OF A MULTISPECIFIC BINDER - Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody that specifically binds to a second binding site of the multispecific antibody, which is different from the first binding site, and thereby depleting the multispecific antibody from the sample. | 03-12-2015 |
20150072003 | FORMULATIONS - The present invention relates to a hygroscopic matrix based composition, a process for the preparation thereof and its use in the treatment of diseases. | 03-12-2015 |
20150065516 | NEW BIARYL AMIDE DERIVATIVES - The invention provides novel compounds having the general formula (I) | 03-05-2015 |
20150064746 | METHOD FOR REDUCTION OF 1->3 READING FRAME SHIFTS - Herein is reported a method for the recombinant production of a polypeptide, which comprises the tripeptide QKK, characterized in that the method comprises the step of recovering the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the tripeptide QKK comprised in the polypeptide is encoded by the oligonucleotide cag aaa aaa or the oligonucleotide caa aag aaa. | 03-05-2015 |
20150064735 | METHOD FOR THE DETERMINATION OF SEQUENCE VARIANTS OF POLYPEPTIDES - The current invention is directed to a method for determining amino acid sequence mutations in a produced polypeptide, comprising the following steps of a) providing a sample of a produced polypeptide, b) incubating the polypeptide in the sample with a protease, c) performing a two dimensional analysis using reversed phase chromatography coupled with a high resolution mass spectroscopy (FT-ICR/FT-orbitrap) and MS/MS analysis of the amino acid sequence fragments of the peptides, d) data evaluation by comparing the LC-MS data sets obtained for the samples side by side with the data set of a reference sample, by searching for differences in the signal intensities at given retention times and by evaluation of differential signals with respect to amino acid sequence mutations. The reference sample for data evaluation (d) can be either a well characterized standard or one of the samples to be analyzed. | 03-05-2015 |
20150057296 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE - The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms. | 02-26-2015 |
20150056656 | METHOD FOR REDUCTION OF 1->2 READING FRAME SHIFTS - Herein is reported a method for the recombinant production of a polypeptide, which comprises the dipeptide AR, characterized in that the method comprises the recovering of the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the dipeptide AR comprised in the polypeptide is encoded by the oligonucleotide gca cgt, or the oligonucleotide gcg cgt, or the oligonucleotide gcc cgt. | 02-26-2015 |
20150056186 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent. | 02-26-2015 |
20150045408 | (3,4-DICHLORO-PHENYL)-((S)-3-PROPYL-PYRROLIDIN-3-YL)-METHANONE HYDROCHLORIDE AND MANUFACTURING PROCESSES - The present invention is concerned with a novel process for the preparation of a compound of formula I and its hydrates | 02-12-2015 |
20150045359 | MORPHOLINE COMPOUNDS AND USES THEREOF - The present invention relates to compounds of formula | 02-12-2015 |
20150044287 | CAPECITABINE RAPIDLY DISINTEGRATING TABLETS - There is provided a film coated pharmaceutical composition comprising 5′-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400μ), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Pharmaburst C or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet. This tablet disintegrates in water at 37° C. in a USP Disintegration Apparatus in less than 2 minutes, preferably 1 minute and have a hardness of 8-13 strong Cobb-Units. | 02-12-2015 |
20150044232 | MARKERS FOR THE RESPONSIVENESS TO ANTI-CD44 ANTIBODIES - The present invention relates to means and methods of determining whether a tumor cell or a cancer cell is responsive to an anti-CD44 antibody or to an antigen binding fragment thereof. The method comprises the determination of the major CD44 isoform in a sample, wherein if the major CD44 isoform is CD44s, the tumor cell or cancer cell is responsive to said anti-CD44 antibody. Also means and methods of treating a cancer patient that has been determined to respond to an anti-CD44 antibody are subject of the present invention. | 02-12-2015 |
20150044214 | BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 02-12-2015 |
20150041395 | MICRO FLOW FILTRATION SYSTEM AND FLOW FILTRATION METHOD - A micro flow filtration system comprises a fluid circuitry ( | 02-12-2015 |
20150041375 | MICRO FLOW FILTRATION SYSTEM AND INTEGRATED MICROFLUIDIC ELEMENT - A micro fluid filtration system ( | 02-12-2015 |
20150038523 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 - The invention relates to compounds of formula (I): wherein R | 02-05-2015 |
20150038354 | FULL LENGTH ANTIBODY DISPLAY SYSTEM FOR EUKARYOTIC CELLS AND ITS USE - Herein is reported a method of selecting a cell expressing a bispecific antibody comprising the steps of (a) generating a population of eukaryotic cells by transduction with a population of lentiviral virus particles, whereby each cell of the population of cells displays a membrane-bound full length antibody which is encoded by the lentiviral nucleic acid, and which specifically binds to two or more antigens or two or more epitopes on the same antigen, and (b) selecting from the population of eukaryotic cells a cell depending on the properties of the displayed membrane-bound full length antibody, whereby each lentiviral virus particle of the population of lentiviral virus particles comprises a bicistronic expression cassette comprising the EV71-IRES for the expression of the membrane-bound antibody. | 02-05-2015 |
20150031687 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection - The invention provides novel compounds having the general formula: | 01-29-2015 |
20150025249 | PROCESS FOR THE PREPARATION OF PROPIONIC ACID DERIVATIVES - The invention relates to a process for the preparation of a compound of formula (I) | 01-22-2015 |
20150018241 | FC-RECEPTOR BASED AFFINITY CHROMATOGRAPHY - Herein is reported the use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromatography ligand in general and, for example, for the determination of the in vivo half-live of an antibody by determining the ratio of the retention times of the antibody and a reference antibody. | 01-15-2015 |
20150017674 | METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO VASCULAR BED CELLS - This application relates to a method for differentiating pluripotent stem cells (PSCs) into vascular bed cells. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into vascular bed cells based on linked steps of chemically defined medium inductions. | 01-15-2015 |
20150011556 | PYRROLOPYRAZONE INHIBITORS OF TANKYRASE - There are provided compounds of the formula | 01-08-2015 |
20150011459 | SHORTENED TETRANECTIN-APOLIPOPROTEIN A-1 FUSION PROTEIN, A LIPID PARTICLE CONTAINING IT, AND USES THEREOF - Herein is reported a shortened tetranectin-apolipoprotein A-I fusion protein and a lipid particle comprising the shortened tetranectin-apolipoprotein A-I fusion protein as well as uses thereof. | 01-08-2015 |
20150010567 | BISPECIFIC ANTIBODY MOLECULES WITH ANTIGEN-TRANSFECTED T-CELLS AND THEIR USE IN MEDICINE - The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8 | 01-08-2015 |
20150010540 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD22 ANTIBODY-DRUG CONJUGATE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate. | 01-08-2015 |
20140363901 | Device for Use in the Detection of Binding Affinities - A device for use in the detection of binding affinities comprises a planar waveguide ( | 12-11-2014 |
20140363898 | METHOD FOR THE IDENTIFICATION OF BETA-SHEET AGGREGATED PROTEIN LIGANDS - The present invention provides an assay for the identification of beta-sheet aggregated protein ligands using Thiazine Red R. | 12-11-2014 |
20140356352 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate. | 12-04-2014 |
20140350259 | PROCESS FOR THE PREPARATION OF 2-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES - The invention relates to a novel process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I or of a salt thereof | 11-27-2014 |
20140343032 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION - The invention provides novel compounds having the general formula: | 11-20-2014 |
20140342382 | METHOD FOR THE DETECTION OF A BINDING PARTNER OF A MULTISPECIFIC BINDER - Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase. | 11-20-2014 |
20140336363 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 11-13-2014 |
20140335609 | PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS - The current invention reports a method for the recombinant production of a secreted heterologous immunoglobulin in a CHO cell comprising the following steps: i) providing a CHO cell, which is adapted to growth in suspension culture, adapted to growth in serum-free medium, mycoplasma free, and virus free, ii) providing a vector comprising a prokaryotic origin of replication, a first nucleic acid conferring resistance to a prokaryotic selection agent, a second nucleic acid encoding the heavy chain of said heterologous immunoglobulin, a third nucleic acid encoding the light chain of said heterologous immunoglobulin, a fourth nucleic acid conferring resistance to a eukaryotic selection agent, iii) transfecting said CHO cell, wherein said transfecting comprises a) transfecting said CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a first eukaryotic selection agent, b) selecting a CHO cell by growth in cultivation medium containing said first eukaryotic selection agent, c) transfecting said selected CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a second eukaryotic selection agent different to said first eukaryotic selection agent, d) selecting a CHO cell by selected growth in cultivation medium containing said first and said second eukaryotic selection agent, iv) cultivating said transfected CHO cell in a medium in the presence of said first and second eukaryotic selection agent, under conditions suitable for the expression of said second, and third nucleic acid, and v) recovering said secreted heterologous immunoglobulin from the cultivation medium. | 11-13-2014 |
20140335084 | ANTIBODY FORMULATION - The present invention relates to an anti-CD44 monoclonal antibody formulation, a process for the preparation of said formulation and uses thereof. | 11-13-2014 |
20140330008 | PROCESS FOR THE PREPARATION OF BORONIC ACID INTERMEDIATES - The present invention relates to a process for the preparation of 2-amino-pyrimidine-5-boronic acid of formula (I). | 11-06-2014 |
20140329806 | NOVEL SOLID FORMS - The instant invention relates to novel solid forms of the compound of formula (I) | 11-06-2014 |
20140329277 | METHOD FOR CULTURING CELLS IN ORDER TO PRODUCE SUBSTANCES - The invention concerns a method for culturing cells in order to produce substances. According to the invention a cell line producing substances is cultured while feeding a nutrient medium in such a manner that glucose limitation occurs in the culture solution. The degree of glucose limitation DGL=qGlc/qGlc | 11-06-2014 |
20140314771 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND TLR9 AGONIST - The present invention relates to the combination therapy of antibodies against human CSF-1R with a TLR9 agonist. | 10-23-2014 |
20140305195 | PREPARATIVE COLUMN CHROMATOGRAPHY SYSTEM - A chromatography system comprising a mixing circuit or a mixing chamber, a bubble trap, a concentration detector and one or more pumps, characterized in that the bubble trap has a permanent opening at its highest point is described herein. Furthermore, a chromatography system is described, characterized in that it contains two concentration detectors the first of which is located in the mixing circuit or the mixing chamber and the second is located downstream of the main pump. | 10-16-2014 |
20140303149 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS - Compounds of the formula I or II: | 10-09-2014 |
20140303141 | TRIAZOLOPYRIDINE COMPOUNDS - The invention is concerned with triazolopyridine compounds of formula (I) | 10-09-2014 |
20140302559 | RAPID METHOD FOR CLONING AND EXPRESSION OF COGNATE ANTIBODY VARIABLE REGION GENE SEGMENTS - In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformed | 10-09-2014 |
20140302019 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall survival and/or progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. | 10-09-2014 |
20140302015 | ANTIBODIES AGAINST HUMAN IL33R AND USES THEREOF - An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases. | 10-09-2014 |
20140294811 | METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY - The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene. | 10-02-2014 |
20140288046 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES - The invention relates to a compound of formula (I) | 09-25-2014 |
20140273279 | METHOD FOR DETERMINING THE BINDING CONSTANT OF HIGH AFFINITY COMPOUNDS - The invention relates to a method for determining the binding constant of a compound of interest to proteins comprising the following steps: a) adding the high affinity compound to a two-chamber system, wherein the two chambers are separated by a semipermeable membrane, which is permeable for the compound of interest, and determining the amount of the high affinity compound of interest in one of the chambers after the distribution equilibrium has been reached, b) adding a sink compound to one of the chambers whereby the sink compound can not permeate the membrane, and determining the distribution coefficient of the compound of interest to the sink compound after the distribution equilibrium has been reached, c) adding an unspecific protein to the other chamber, whereby the unspecific protein can not permeate the membrane, and determining the distribution coefficient of the compound of interest to the unspecific protein in presence of a sink compound after the distribution equilibrium has been reached, and d) determining the binding constant of the test compound with the distribution coefficient of steps b) and c). | 09-18-2014 |
20140256915 | Velocity Factor - The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method. | 09-11-2014 |
20140243508 | METHOD FOR THE PURIFICATION OF ANTIBODIES - A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of an immunoglobulin from an ion exchange resin is described. | 08-28-2014 |
20140243325 | 1,3-Oxazines as Bace1 and/or Bace2 Inhibitors - The present invention provides 4-(3-Amino-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamines of formula I | 08-28-2014 |
20140242028 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I: | 08-28-2014 |
20140234899 | PROCESS FOR ANTIBODY G1 GLYCOFORM PRODUCTION - The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment or immunoglobulin fusion with G1 glycostructure comprising incubating with a galactosyltransferase, a sialyltransferase, a beta-1,4-galactosidase and a sialidase, whereby the galactosyltransferase is added in more than one aliquot during the incubating. | 08-21-2014 |
20140221360 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES - This invention relates to compounds of formula I, | 08-07-2014 |
20140221350 | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists - The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior. | 08-07-2014 |